Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 13;10:1157. doi: 10.3389/fphys.2019.01157

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Hu, Xie, Luo, Feng, Liu, Han, Kong, Zou, Wang and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Time-course changes in AQP2 (A,C) and IL-1β (B,D) protein and mRNA levels in the kidneys of BUO, B-R1D, and B-R3D mice. (E) Correlation between AQP2 and IL-1β protein expression in the obstructed kidneys of B-R3D mice (n = 9). (F) V2R mRNA levels in the kidneys of BUO, B-R1D, and B-R3D mice. IL-1β, interleukin-1β; V2R, vasopressin type 2 receptor; Sham, sham-operated groups; BUO, bilateral ureteral obstruction for 24 h; BUO + Ali, BUO group with aliskiren treatment; B-R1D, BUO for 16 h followed by 1 day release; B-R1D + Ali, B-R1D group with aliskiren treatment; B-R3D, BUO for 16 h followed by 3 days release; B-R3D + Ali, B-R3D group with aliskiren treatment; OBS, obstructed group; OBS + Ali, obstructed group with aliskiren treatment.